CMS made the wrong decision on Aduhelm. But there might be a silver lining.

The Centers for Medicare and Medicaid Services (CMS) issued on Thursday itshotly debated final decision on whether to cover aducanumab (Aduhelm), the first

FDA-approved treatment for Alzheimer’s that slows the disease’s biological progression rather than just temporarily easing its symptoms. We believe it made the wrong choice.